| Business Summary | | Seattle
Genetics,
Inc.
(SGEN)
discovers
and
develops
monoclonal
antibody-based
drugs
to
treat
cancer
and
related
diseases.
SGEN
has
four
monoclonal
antibody-based
technologies:
monoclonal
antibodies;
monoclonal
antibodies
chemically
linked
to
cell-killing
drugs,
or
monoclonal
antibody-drug
conjugates;
single
proteins
containing
monoclonal
antibody
and
toxin
components,
or
single-chain
immunotoxins;
and
antibody-directed
enzyme
prodrug
therapy
(ADEPT).
The
Company's
technologies
enable
it
to
increase
the
potency
and
efficacy
of
monoclonal
antibodies
that
have
specificity
for
cancer
or
related
diseases
but
are
not
potent
enough
on
their
own.
SGEN
has
constructed
a
diverse
portfolio
of
drug
candidates
targeted
to
many
types
of
human
cancer.
The
Company's
four
technologies
provide
it
with
the
means
to
discover
and
develop
monoclonal
antibody-based
drug
candidates
internally
as
well
as
to
partner
its
technology
with
other
companies
also
developing
monoclonal
antibodies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Seattle
Genetics
Inc.
discovers
and
develops
monoclonal
antibody
based
drugs
to
treat
cancer
and
related
diseases.
SGEN
has
four
mAb-based
technologies:
engineered
mAbs;
mAb-drug
conjugates;
single-chain
immunotoxins;
and
antibody-directed
enzyme
prodrug
theragy.
For
the
six
months
ended
6/30/01,
revenues
fell
38%
to
$35
thousand.
Net
loss
applicable
to
Common
totalled
$9.4
million,
up
from
$2.1
million.
Results
reflect
the
absence
of
government
grants
and
an
increase
in
R&D
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Charles Waite, Jr., 45 Chairman | -- | H. Perry Fell, Ph.D., 43 CEO,
Director | $240K | Clay Siegall, Ph.D., 40 Pres,
CSO | 240K | Tim Carroll, 49 CFO | 81K | Morris Rosenberg VP,
Devel. | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|